Impact News +++ Surmodics jumps amid pre-trial hearing in FTC′s suit to block sale to GTCR (SeekingAlpha) +++ SURMODICS Aktie +6,25%

ALDEYRA Aktie

>ALDEYRA Aktienkurs

4.647 EUR +0.5% (Tradegate)

Ask: 4.421 EUR / 3400 Stück

Bid: 4.374 EUR / 3500 Stück

Tagesumsatz: 170 Stück

Realtime Kurs von 8 bis 22 Uhr!

ALDEYRA Aktie über LYNX handeln

Intraday

1 Jahr

>ALDEYRA Performance

1 Woche: -1,3%

1 Monat: +49,6%

3 Monate: +102,7%

6 Monate: -1,5%

1 Jahr: +26,6%

laufendes Jahr: -3,3%

>ALDEYRA Aktie

Name:

ALDEYRA THERAPEUT.DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US01438T1060 / A111X8

Symbol/ Ticker:

137 (Frankfurt) / ALDX (NASDAQ)

Kürzel:

FRA:137, ETR:137, 137:GR, NASDAQ:ALDX

Index:

Webseite:

https://www.aldeyra.com/

Marktkapitalisierung:

272.65 Mio. EUR

Umsatz:

EBITDA:

-51.72 Mio. EUR

Gewinn je Aktie:

-0.82 EUR

Schulden:

13.22 Mio. EUR

Liquide Mittel:

42.76 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -91.77%

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

- / 4.66 / -0.06

Gewinnm./ Eigenkapitalr.:

- / -65.19%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

ALDEYRA

Letzte Datenerhebung:

25.07.25

>ALDEYRA Eigentümer

Aktien: 59.9 Mio. St.

f.h. Aktien: 47.67 Mio. St.

Insider Eigner: 3.13%

Instit. Eigner: 56.17%

Leerverk. Aktien: 7.77%

>ALDEYRA Peer Group

AKEBIA

BIO-RAD A

CLEARSIDE BIOMEDICAL

CODEXIS

DELCATH

EVOLENT HEALTH

IMUNON

INTEGRA LIFESCIENCES

LIFEVANTAGE

PACIFIC BIOSCIENCES

>ALDEYRA Chart & Kurs - NASDAQ

>ALDEYRA News

17.07.25 - 13:45	Aldeyra says FDA accepted resubmitted marketing application for lead drug (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.07.25 - 19:45	Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
	Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....

17.06.25 - 16:45	Aldeyra resubmits Reproxalap′s marketing application to FDA (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.25 - 23:48	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX (PR Newswire)
	NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

06.05.25 - 22:03	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX (PR Newswire)
	NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

29.04.25 - 15:51	ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm (PR Newswire)
	LOS ANGELES, April 29, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of the securities laws.......

29.04.25 - 00:09	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX (PR Newswire)
	NEW YORK, April 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

24.04.25 - 15:16	ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm (PR Newswire)
	LOS ANGELES, April 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of the securities laws.......

22.04.25 - 22:01	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX (PR Newswire)
	NEW YORK, April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

17.04.25 - 13:03

Aldeyra Therapeutics Appoints Chip Clark to Board of Directors (Business Wire)

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. “Chip possesses a wealth of experience leading innovative biotechnology companies,” stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. “We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases.” Mr. Clark has more than three decades of leadership experience in the biopharmaceutical industry. He currently serves as Co-founder and Chief Executive Officer of Vibrant Biomedicines, a venture-backed company developing vaccines that target bacterial pathogens. Before co-founding Vibrant Biomedicines, Mr. Clark served as Chief Executive Officer ...

15.04.25 - 00:21	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX (PR Newswire)
	NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

10.04.25 - 15:30	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA′s Reproxalap Complete Response Letter - Hagens Berman (PR Newswire)
	SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter ("CRL") from the FDA for the resubmission of the New......

08.04.25 - 05:01	Insiderhandel: Insider verkauft Aktien von Aldeyra The im Wert von 4828000 USD (Insiderkauf)
	Perceptive Advisors LLC - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-04-03...

03.04.25 - 16:33	XFRA: 137: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN ALDEYRA THERAPEUT.DL-,001 137 US01438T1060 AB/FROM ONWARDS 03.04.2025 16:24 CET...

03.04.25 - 15:51	FDA Rejects Aldeyras Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns (Benzinga)
	The FDA rejected Aldeyra's resubmission for reproxalap, citing efficacy concerns. The company plans another trial and aims to resubmit the NDA by mid-2025. read more...

03.04.25 - 14:51	Aldeyra tumbles as FDA snubs dry eye disease therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.04.25 - 14:18	XFRA: INSTRUMENT_SUSPENSION - US01438T1060 (XETRA)
	Instrument ID [8902382] (137 - US01438T1060) suspended...

03.04.25 - 14:18	XFRA: 137: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL ALDEYRA THERAPEUT.DL-,001 137 US01438T1060 BAW/UFN...

09.12.24 - 17:18	Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? (Zacks)
	Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately....

19.11.24 - 17:18	ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap (Zacks)
	The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Herr wird denen entgegenkommen, die verstehen, in den Tag hinein zu leben, immer ihre Pflicht tun, mit Ruhe, Würde und Geduld, ohne sich den Kopf heiß zu machen wegen der Dinge, die morgen oder in Zukunft geschehen können. - Papst Johannes XXIII.

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram